| Literature DB >> 26076029 |
Seung Mi Lee1, Joong Shin Park2, Errol R Norwitz3, Sun Min Kim2, JoonHo Lee2, Chan-Wook Park2, Byoung Jae Kim1, Jong Kwan Jun2.
Abstract
OBJECTIVE: Presenting twins are less likely to develop respiratory complications than non-presenting twins. The precise reason for this difference is not well understood, although it is known that the presence of inflammation reduces the risk of respiratory morbidity at birth. To further investigate this association, we compared the concentrations of inflammatory biomarkers in mid-trimester amniotic fluid (AF) of asymptomatic twin pairs. STUDYEntities:
Mesh:
Substances:
Year: 2015 PMID: 26076029 PMCID: PMC4468219 DOI: 10.1371/journal.pone.0125346
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of the study population.
| Characteristics | Twin pairs |
|---|---|
| (n = 82) | |
| Maternal age (years) | 35 ± 3 |
| Nulliparity | 59 (72%) |
| Gestational age at amniocentesis (weeks) | 17.0 ± 0.7 |
| Indication for amniocentesis | |
| Advanced maternal age | 68 (83%) |
| Abnormal serum screening | 8 (10%) |
| Abnormal ultrasound | 1 (1%) |
| Maternal request | 5 (6%) |
| Gestational age at delivery (weeks) | 37.8 ± 0.7 |
| Birth weight (grams) | 2723 ± 337 (presenting twin) / 2667 ± 377 (non-presenting twin) |
| Cesarean delivery | 54 (66%) |
* p = NS between presenting and non-presenting twins (analyzed with Wilcoxon signed rank test).
Concentrations of analytes in mid-trimester amniotic fluid in presenting versus non-presenting twins.
| Characteristics | unit | Presenting twin | Non-presenting twin | P value | Percent <LLOQ |
|---|---|---|---|---|---|
| (n = 82) | (n = 82) | ||||
| IL-1β | pg/mL | 1.67 ± 1.23 | 1.66 ± 1.26 | NS | 100 |
| IL-2 | pg/mL | 2.82 ± 2.62 | 3.25 ± 3.33 | NS | 84.1 |
| IL-4 | pg/mL | 0.36 ± 0.24 | 0.36 ± 0.24 | NS | 98.2 |
| IL-5 | pg/mL | 1.23 ± 1.54 | 1.23 ± 1.57 | NS | 100 |
| IL-6 | pg/mL | 350.98 ± 542.31 | 279.52 ± 428.32 | NS | 1.2 |
|
|
|
|
|
|
|
| IL-10 | pg/mL | 3.45 ± 1.82 | 3.51 ± 1.69 | NS | 97.6 |
| IL-12 | pg/mL | 3.43 ± 1.81 | 3.07 ± 1.66 | 0.091 | 99.4 |
| IL-13 | pg/mL | 1.68 ± 1.63 | 1.67 ± 1.71 | NS | 100 |
| IL-15 | pg/mL | 6.07 ± 7.12 | 6.17 ± 6.67 | NS | 60.4 |
| GM_CSF | pg/mL | 25.41 ± 8.36 | 24.61 ± 7.39 | NS | 0.0 |
| IFN-r | pg/mL | 7.61 ± 10.78 | 6.46 ± 8.37 | NS | 80.5 |
| TNF-a | pg/mL | 6.19 ± 2.94 | 6.26 ± 2.77 | NS | 100 |
| MMP-1 | pg/mL | 760.96 ± 874.26 | 742.51 ± 855.49 | NS | 0.0 |
| MMP-2 | pg/mL | 167922.2 ± 57259.1 | 167635.6 ± 63210.0 | NS | 0.0 |
| MMP-3 | pg/mL | 1654.33 ± 910.69 | 1598.21 ± 956.81 | NS | 0.0 |
|
|
|
|
|
|
|
| MMP-9 | pg/mL | 714.68 ± 584.30 | 673.85 ± 516.87 | NS | 7.3 |
| MMP-12 | pg/mL | 21.76 ± 31.86 | 23.68 ± 38.30 | NS | 57.9 |
| Complement factor D | ng/mL | 1292.9 ± 510.3 | 1215.0 ± 603.9 | NS | 0.0 |
| Serpin E1 | ng/mL | 177.7 ± 98.2 | 158.5 ± 100.1 | 0.052 | 0.0 |
| Adiponectin | ng/mL | 68.4 ± 35.6 | 61.1 ± 33.8 | 0.052 | 0.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LLOQ, lower limit of quantification; NS, not significant.
* analyzed with Wilcoxon signed rank test.
† Significant after adjustment for fetal growth restriction and chorionicity.